CTOR

Citius Oncology, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$0.52

Price (1 Year)

$1.39 $0.51

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %7.5 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %2.3 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.

Website

Analysis (Turkish): CTOR Hissesi Caiz mi, Helal mi? Citius Oncology, Inc. Katılım Analizi